Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Chermside, Australia Clinical Trials

A listing of Chermside, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (26) clinical trials

A Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

This study is sponsor-open, investigator-blinded, participant-blinded, randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study that will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7049389 following oral administration in healthy volunteers and chronic HBV infected participants. The effect of food on the PK of RO7049389 and ...

Phase

4.24 miles

Learn More »

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, an ...

Phase

4.24 miles

Learn More »

A Trial of KB004 in Patients With Glioblastoma

This is a study of drug KB004 in patients with recurrent glioblastoma (GBM). Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM ...

Phase

4.24 miles

Learn More »

Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis

This is a multicenter, open-label, two-population, single-arm study with a sequential, interpatient dose-escalation and dose expansion in adult subjects with progressive forms of MS (Population A) and in adult subjects with RRMS (Population B). This study will evaluate the safety of ATA188 administered by intravenous (IV) infusion. ATA188 will be ...

Phase

4.31 miles

Learn More »

First-in-Human Trial of Single Ascending Dose Multiple Ascending Dose and Malaria Challenge Model in Healthy Subjects

The primary purpose of this study is to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy subjects following infection with Plasmodium falciparum.

Phase

4.44 miles

Learn More »

A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

Tumor microenvironment plays an important role in the interaction of immune cells with cancer . The identification of programmed cell death receptor 1 (PD-1) and programmed death ligand-1 (PD-L1) have provided the scientific rationale and supports the clinical development of agents targeting this pathway. Currently, PD-1 and PD-L1 inhibitory pathway ...

Phase

5.55 miles

Learn More »

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the checkpoint inhibitor pembrolizumab (Part II), in patients with locally advanced primary and recurrent colorectal cancer scheduled to ...

Phase

5.8 miles

Learn More »

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.

Phase

5.8 miles

Learn More »

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Studies have shown that mTOR inhibitors (MTI) inhibit growth of pre-B and T-cell ALL cell lines in vitro and in ALL xenograft models. The MTI temsirolimus was chosen for use in this study due to its weekly intravenous dosing, its more predictable blood levels, and availability of a single-agent pediatric ...

Phase

5.8 miles

Learn More »

Phase 1 Study of Safety and Biological Effects of C326 an Inhibitor of IL-6 in Crohn s Disease

Determination of safety is the most important goal of this first study with C326. Other goals of the study are to examine: - pharmacokinetics (change in serum concentrations over time), - biological activity (change in blood markers relecting activity of Crohn's Disease), - effects on symptoms of Crohn's disease. Participants ...

Phase

5.8 miles

Learn More »